How does Swiss Authorized Representative Designation Impact EU Market Access?
Swiss authorized representatives can facilitate EU medical device market access despite Brexit changes.
Resources & News
Stay informed with real-time regulatory news and expert insights, and keep the conversation going by connecting with us on social media.
Showing 262–270 of 396
What is a Swiss Authorized Representative for Medical Devices?
Discover essential Swiss authorized representative requirements for medical devices and avoid costly compliance violations.
Do I Need German Language Documents to Sell Medical Devices?
German translations required for medical device IFUs and labeling, adding 4-8 weeks to market entry timeline.
What Are German-Specific Requirements for Medical Devices?
Germany's medical device requirements extend beyond EU MDR with unique BfArM obligations and documentation standards.
Can I Sell Medical Devices in Ireland with UK Approval?
Brexit ended UK-Ireland medical device recognition. Learn new CE marking and HPRA registration requirements for Irish market access.
Should You Enter Emerging Markets Early or Late in Your Expansion Strategy?
Timing your emerging markets expansion requires balancing opportunity against risk. Early market entry lets you build first-mover advantages and shape regulatory frameworks, but demands sustained investment with delayed returns. Late entry reduces uncertainty and leverages established infrastructure, yet may cost you competitive positioning. Medical device companies must evaluate regulatory maturity, market size, competitive landscape, and resource availability to determine optimal entry timing. A portfolio approach—entering some markets early while waiting on others—balances growth momentum with risk management across your international expansion strategy.
How Do Reimbursement Landscapes Impact Market Entry Sequencing?
Reimbursement landscapes fundamentally shape your medical device market entry strategy by determining revenue generation speed and resource requirements. Markets with established reimbursement pathways enable faster commercial returns, while emerging systems demand extensive evidence development and longer timelines. This guide explores how to evaluate payer structures, balance quick-win markets against strategic opportunities, and align regulatory approval with reimbursement processes. Discover proven sequencing strategies that optimize resource allocation and accelerate global market access.
RAPS Convergence 2025 MedEnvoy Key Takeaways
From October 7–9, the MedEnvoy team attended RAPS Convergence 2025 in Pittsburgh, joining global leaders, innovators, and policymakers to…
Economic Operators Under the MDR and IVDR
This webinar breaks down the roles and responsibilities of economic operators under the MDR and IVDR.
Showing 262–270 of 396